Cheap Tadalafil

Cialis is probably the second most famous erectile dysfunction drug available on the market today. Launched in 2003 it has been a very popular alternative to the first erectile dysfunction drug Viagra. Cialis is made with a compound called tadalafil that is able to block the enzyme phosphodiasterase-5 that breaks down cyclic guanosine monophosphate that is essential in the making sure that an erection happens. It is these low levels of cGMP that often result in erectile dysfunction.

It has been estimated that nearly 40% of males of the age of forty have experienced some form of erectile dysfunction and this figure rises to 50% by the age of 50. The amount of ED sufferers continues upwards with age and by the age of 80 almost all men have erectile dysfunction in some way. In the days before the erectile dysfunction drugs it was expected that an older man would just have to resign himself to a life of no sex, but now with Cialis, Viagra and others this is not the case anymore.

Cialis has a number of advantages over Viagra. For example Viagra only works for four hours and so sex must be planned and also Viagra can’t be taken after a big meal as fatty food reduces the efficiency of Viagra. Cialis however works for 36 hours at a stretch so sex can be had at anytime during that period and you can take your time. Cialis is fast becoming known as the The Weekend Pill. Cialis also has the advantage of not interacting with diet so it can be taken at anytime.

People who use Cialis say that the advantage of the drug is that partners can be spontaneous and impulsive in their love making and they dont have to worry about eating and timing before sex. If you suffer from erectile dysfunction Cialis could be the answer for you.

Pressure is on the management of Eli Lilly who are soon hoping to acquire the 50% share of the Cialis drug that belongs to ICOS, to increase their offer of $32 dollars a share as the results from 4th quarter preliminary figure show that Cialis is beating its own sales forecasts issued by the company. The information on the higher than expected sales is likely to raise a few eyebrows as some smaller shareholders have been saying that the offer is too low for the 2nd best selling erectile dysfunction drug in the world. The date for the final vote on whether the 2.1 billion dollar deal goes ahead is set for December 19th and this new news will only make the deal less likely to go ahead at this price.
One market analyst Lehman Brothers raised its target price for the shares in Cialis to $34 dollars but HealthCor that own almost 5% of the stock said that $40dollar per share is a much more realistic price for the impotence drug that some see in the near future as beating Viagra to the top spot in the erectile dysfunction stakes.

Not only are the sales of Cialis continuing to rise but the value of the complete erectile dysfunction drug market is constantly growing worldwide and new markets are always being tapped. The increase in sales in going to have a big effect on profits that should put them in the region of over 20 million dollars which is much more that the middle estimate of around 11 million dollars that was forecasted recently.

It seems like the lone voices of just a few shareholders and the recommendation of the ISS that we reported on recently at Ukmedix are now making more sense and Eli Lilly should have more of a fight on their hands to get all the shares of the ICOS company.

Cialis is Viagra’s main rival and the feeling is mutual. Cialis has been the biggest factor in Viagra’s reducing market share of the impotence drug market. Ukmedix will be reporting from the shareholders meeting scheduled for January 19th 2006 to see gets full control of the wonder drug Cialis.

The recent sales figures for the 4th quarter that were released recently for the drug Cialis will have market analysts questioning the wisdom of Icos selling out to Eli Lilly at a share price of $34 per share. The figures show an almost 30% increase in sales from the same period a year ago at nearly $270 million dollars.

Overall the drug sold just under 1 billion dollars over the whole of 2006 making it the second best selling impotence drug in the world. In 2005 the sales for Cialis were just under $750 million dollars. The profits that the Cialis drug brought in were much increased due to the fact that last year spending in Marketing was reduced and this is partly because Cialis is slowly becoming as famous as Viagra the no.1 selling impotence drug from Pfizer and thus it needs less marketing for its sales.

The policy of huge marketing budgets for Cialis is now paying off and the rewards are being reaped. In the United States Cialis costs about $12 for one tablet and many see this a very good value because the drug works for as long as 35 hours in some cases rather than just 4 hours in the cases of Viagra and Levitra.

The vote on the full control of Cialis is expected to take place on January 25th and Eli Lilly is confident that they will get enough shareholder votes for the deal to go ahead. The biggest opponent of the deal is a 5% shareholder called HealthCor that claims that the commercial possibilities of Cialis have not been fully tapped in the erectile dysfunction markets and also in other possible uses for Cialis such as the treatment of pulmonary arterial hypertension.

HealthCor believes that a price of $40 per share is a more realistic valuation of the company and as such they intend to vote against the deal.